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Abstract
Objective—Inflammation in the bone microenvironment stimulates osteoclast differentiation,
resulting in uncoupling of resorption and formation. Mechanisms contributing to the inhibition of
osteoblast function in inflammatory diseases, however, have not been elucidated. Rheumatoid
arthritis (RA) is a prototype of an inflammatory arthritis that results in focal loss of articular bone.
The paucity of bone repair in inflammatory diseases such as RA raises compelling questions
regarding the impact of inflammation on bone formation. The aim of this study was to establish
the mechanisms by which inflammation regulates osteoblast activity.
Methods—We characterized an innovative variant of a murine model of arthritis in which
inflammation is induced in C57BL/6J mice by transfer of arthritogenic K/B×N serum and allowed
to resolve.
Results—In the setting of resolving inflammation, bone resorption ceased and appositional
osteoblast-mediated bone formation was induced, resulting in repair of eroded bone. Resolution of
inflammation was accompanied by striking changes in the expression of regulators of the Wnt/β-
catenin pathway, which is critical for osteoblast differentiation and function. Down-regulation of
the Wnt antagonists secreted frizzled-related protein 1 (sFRP1) and sFRP2 during the resolution
phase paralleled induction of the anabolic and pro–matrix mineralization factors Wnt10b and
DKK2, demonstrating the role of inflammation in regulating Wnt signaling.
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Conclusion—Repair of articular bone erosion occurs in the setting of resolving inflammation,
accompanied by alterations in the Wnt signaling pathway. These data imply that in inflammatory
diseases that result in persistent articular bone loss, strict control of inflammation may not be
achieved and may be essential for the generation of an anabolic microenvironment that supports
bone formation and repair.
Inflammation-induced pathologic bone loss is characterized by activation of bone resorption
and inhibition of bone formation. Although the stimulatory effects of inflammation on
osteoclast-mediated bone resorption are well established (1–3), the impact of
proinflammatory cytokines on osteoblast function in vivo requires further elucidation (4).
Tumor necrosis factor (TNF) has been shown to suppress osteoblast maturation in vitro by
inhibiting the expression of runt-related transcription factor 2 (RUNX-2) (5), a transcription
factor that is responsible for osteoblast-lineage commitment and gene expression. As a
result, expression of the RUNX-2 target genes type I collagen, alkaline phosphatase, and
osteocalcin (OCN) is suppressed. Bone matrix deposition and mineralization are thus
impaired by TNF (6). Interleukin-1β (IL-1β) elicits similar inhibitory responses in
differentiating osteoblasts (7,8). Furthermore, proinflammatory cytokines disrupt the Wnt
signaling pathway (9,10), an anabolic pathway that induces the differentiation and
maturation of osteoblasts. In this pathway, a family of secreted agonists activate downstream
signaling, stabilizing β-catenin, a transcriptional coactivator of osteoblast target genes,
including RUNX2 (11,12). Regulation of Wnt signaling is maintained by a number of
secreted antagonists, including members of the secreted frizzled-related protein (sFRP) and
Dickkopf (DKK) families.
Inflammation-induced focal bone loss is perhaps best exemplified in rheumatoid arthritis
(RA), a disease in which osteoclastic resorption leads to the development of articular bone
erosions. In the inflamed microenvironment of the RA joint, osteoblast maturation and
function are compromised. Studies have shown that although osteoblasts are located in the
vicinity of focal articular bone erosions in RA (13) and murine inflammatory arthritis, few
mature osteocalcin-expressing osteoblasts are directly associated with eroded bone surfaces
(14,15). In the serum transfer model of arthritis, a murine model of inflammatory arthritis,
the paucity of alkaline phosphatase and OCN-expressing osteoblasts at erosion sites
correlates with limited bone formation (15). Furthermore, up-regulated expression of Wnt
signaling antagonists has been implicated in the suppression of osteoblast activity during
inflammation-induced bone loss (9,15).
With aggressive treatment of inflammation in RA, bone resorption is suppressed. Although
osteoblast-mediated repair of bone erosions occurs, it is infrequent (16,17), and when repair
is observed, it correlates with well-controlled clinical disease (18,19). This observation
suggests that in patients in whom repair is not detected, subclinical inflammation in the joint
may persist, suppressing erosion repair by osteoblasts. We therefore hypothesized that
resolution of inflammation would stimulate osteoblast function and ultimately result in the
repair of established focal bone erosions. To address this hypothesis, we utilized an
innovative variant of the serum transfer model of arthritis, in which inflammation was
induced and subsequently allowed to resolve. Using this model, we determined the capacity
of osteoblast-lineage cells to recover from inflammation-induced suppression of function
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and subsequently form bone at erosion sites. For the first time, we show that resolution of
inflammation is accompanied by a significant increase in bone formation at previous
inflammation–bone interfaces, correlating with altered synovial expression of Wnt signaling
components that favor anabolic signaling.
Materials and Methods
K/B×N murine serum transfer model of inflammatory arthritis
All animal procedures were performed in accordance with protocols approved by the
Institutional Animal Care and Use Committee at the University of Massachusetts Medical
School. KRN T cell–transgenic mice (provided by Drs. O. Benoist and D. Mathis, Harvard
Medical School and the Institut de Genetique et de Biologie Moleculaire et Cellulaire,
Illkirch, France) were crossed with NOD/ShiLtJ mice (The Jackson Laboratory) to generate
K/B×N mice in which arthritis develops spontaneously (20,21). At 60 days of age,
arthritogenic serum was obtained and pooled for studies, as previously described (2,15).
Serum transfer arthritis was induced in 12-week-old male C57BL/6J mice (The Jackson
Laboratory) by intraperitoneal injection of 150 μl of arthritogenic serum on days 0, 2, and 7.
Nonarthritic mice received 150 μl of sterile phosphate buffered saline at each time point.
The method for scoring clinical inflammation was adapted from a previously described
scoring system (22). For each paw, a score from 0 to 3 was assigned based on the following
criteria: 0 = normal, 1 = slight swelling on the top and bottom of the paw, 2 = obvious
swelling that obscures bone landmarks, and 3 = severe swelling that further obscures bone
landmarks. Scores of the 4 paws were summed, and the average clinical score for each group
was reported.
Histopathologic analyses
For histologic scoring of inflammation and bone erosion, sections were stained with either
hematoxylin and eosin or tartrate-resistant acid phosphatase (TRAP). For TRAP staining,
sections were incubated in 0.1M Tris HCl, pH 9.0, for 18 hours, followed by 0.1M sodium
citrate, pH 5.2, for 3 hours (23). Activated sections were incubated for 30 minutes at 37°C in
0.005% Napthol AS-MX phosphate (Sigma)/0.01% N,N-dimethylformamide/0.03% Fast
Red Violet LB salt (Sigma)/50 mM sodium tartrate in 0.1M acetate, pH 5.0 (24,25) and
counterstained with hematoxylin. Slides were scored by 2 independent observers (MMM
and EMG) using a previously defined histopathologic scoring criteria (2). The data are
presented as the average of the scores of both observers. As previously described (15),
digoxigenin-labeled antisense and sense riboprobes specific for alkaline phosphatase and
OCN messenger RNA (mRNA) were synthesized and used to perform in situ hybridization
on serial tissue sections.
Micro–computed tomography (micro-CT)
The hind paws of the mice were imaged at the Musculoskeletal Imaging Core at the
University of Massachusetts Medical School, using a Scanco Medical μCT 40 with an
isotropic voxel size of 8 μm, at 70 kVp and 114 μA. Images were reconstructed in 1,024 ×
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1,024–pixel matrices. A threshold of 220–1,000 Hounsfield units was used for segmentation.
Axial slices were reformatted to lateral slices and are shown at 3× magnification.
Dynamic histomorphometric analysis
For histomorphometric analysis of in vivo bone formation, mice were administered 50
mg/kg of alizarin and/or 30 mg/kg of calcein by intraperitoneal injection. For quantitative
analysis, mice were given alizarin 13 days prior to being killed and calcein 3 days prior to
being killed (10-day interlabel period). Mice killed on day 10 received alizarin on day 5. As
previously shown (15), the navicular bone of the midfoot is a reproducible site of bone
erosion in the serum transfer model of arthritis, and as such, this site was chosen for
quantitative measurements. Specifically, cortical and endosteal surfaces within the navicular
bone where pannus and inflammatory tissue invaded were analyzed separately from surfaces
contacting normal marrow/connective tissue. Following the resolution of active
inflammation, the appearance of abnormal marrow, loss of adipocytic structure, and tissue
fibrosis were used to identify areas where inflammatory tissue had been present earlier
during the course of arthritis. The mineralized surface/bone surface (MS/BS), mineral
apposition rate (MAR), and bone formation rate/bone surface (BFR/BS) were determined as
previously described (15), using the guidelines established by Parfitt et al (26). For the
nonarthritic group, data for mice killed on days 10, 28, 38, and 48 (n = 15 total) were
combined.
Synovial gene expression
Synovial and associated soft tissue were isolated from the region of the tibiotalar joint and
processed for RNA, as previously described (15). Total RNA (150 ng) was used for iScript
complementary DNA (cDNA) synthesis (Bio-Rad). Quantitative reverse transcription–
polymerase chain reaction (RT-PCR) analysis was performed on diluted cDNA samples
using iScript SYBR Green RT-PCR mix (Bio-Rad) and an Eppendorf realplex quantitative
PCR system. All primers were obtained from Qiagen, except for sFRP1 primers, which were
obtained from Eurofins MWG Operon. Gene expression was normalized to the expression of
HMBS, a housekeeping gene, and data are expressed as the fold increase in gene expression
in arthritic mice compared with that in nonarthritic mice averaged over the course of the
experimental time points (n = 7–8 mice in each group per time point), using the 2−ΔΔCt
method (27). Gene expression in the nonarthritic controls was stable over time in
comparison with HMBS, and similar variability in gene expression among individual mice
was observed at each time point.
Serum measurements
TRAP-5b levels were determined by activity assay (Immunodiagnostic Systems) according
to the manufacturer's instructions.
Statistical analysis
Statistical analysis of the quantitative RT-PCR data was performed using a type III F test of
homogeneity from analysis of variance (ANOVA) modeling to determine if differences
existed among the days. For genes with a P value of ≤ 0.05, the relative expression on day
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10 was tested against the relative expression on subsequent days, using a standard 2-group t-
test assuming independent observations. An informal Bonferroni correction for significance
(0.05/5 = 0.01) was used. Outliers (defined as the mean ± 3SD) were removed prior to
statistical analysis.
ANOVA with a Dunnett's post-test was used to determine statistical significance for the
histomorphometry data, where samples from the nonarthritic controls served as the
comparator control. Student's unpaired t-tests were used to calculate statistical significance
for histology scores and TRAP-5b data.
Results
Association between resolution of inflammation, proinflammatory cytokine expression,
and osteoclastogenesis
To evaluate the effects of abating inflammation on osteoblast activity, we characterized a
variant of the serum transfer model of arthritis (20), in which inflammation was induced
with 3 injections of arthritogenic serum and subsequently allowed to decline. After
administration of arthritogenic serum on days 0, 2, and 7, clinical signs of inflammation
developed rapidly (Figure 1A), peaking on day 10. Synovial tissue isolated from the
tibiotalar joint of arthritic mice showed an up-regulation of IL-1β and TNF mRNA at the
peak of clinical inflammation (Figures 1B and C). In arthritic mice, the expression of IL-1β
mRNA was up-regulated ∼20-fold, and expression of TNF mRNA was up-regulated ∼1.5-
fold compared with nonarthritic controls, consistent with the dominance of IL-1β as the
critical cytokine in this model (28). Up-regulation of proinflammatory cytokines was
accompanied by significant infiltration of inflammatory cells into the joint, synovial
hyperplasia, and invasion of pannus into the marrow cavities of the navicular bone (Figure
2A).
Synovitis promotes osteoclast-mediated articular bone erosion through the up-regulation of
RANKL (2) and reproducibly generates cortical and endosteal bone erosions in the navicular
bone (15). As expected, RANKL mRNA was induced in the synovium of arthritic mice by
day 10 (Figure 1E). In contrast, mRNA expression of osteoprotegerin (OPG), a soluble
decoy receptor that binds RANKL and inhibits osteoclastogenesis, was down-regulated by
the inflammatory process (Figure 1F). As a result, the RANKL:OPG ratio was markedly
elevated on day 10, leading to a significant increase in osteoclast numbers, as measured by
serum TRAP-5b levels (Figure 1G) and osteoclast-mediated bone erosion (Figures 2B and
D). By day 10, the presence of TRAP-positive osteoclasts on the endosteal and cortical
surfaces of the navicular bone was associated with full-thickness cortical defects (Figure
2B). The expression of matrix metalloproteinase 13 (MMP-13), which is implicated in
cartilage destruction and plays a role in preparation of bone surfaces for osteoclast-mediated
resorption (29), was also induced by the inflammatory process (Figure 1D).
With discontinuation of arthritogenic serum injections, clinical inflammation progressively
decreased from day 10 onward (Figure 1A). The expression of IL-1β and TNF mRNA in
synovial tissue decreased rapidly and returned to the levels in nonarthritic controls (Figures
1B and C), resulting in little cellular infiltration in the synovium and decreased synovial
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thickening by day 28 (Figure 2). A decline in proinflammatory cytokine expression was
accompanied by a precipitous down-regulation of RANKL mRNA and up-regulation of
OPG mRNA (Figures 1E and F). The resulting reversal in the RANKL:OPG ratio correlated
with a reduction in the osteoclast number and a marked decrease in active resorption of bone
by day 15 (Figure 2B). During the repair and remodeling phase from day 28 onward, the
absence of IL-1β, TNF, and RANKL mRNA expression paralleled the absence of cellular
infiltrates and osteoclast activity, with a slightly thickened synovium remaining (Figures 2A
and B). Furthermore, bone marrow cavities previously penetrated by inflammatory tissue
were now devoid of normal marrow components and adipocytes (Figure 2A).
The impact of resolving inflammation on bone architecture was evaluated by micro-CT. By
day 15, endosteal and cortical erosion of the ankle and midfoot bones was clearly evident,
resulting in roughened, irregular bone surfaces. Consistent with the histologic data, full-
thickness defects in the midfoot bones were apparent (Figure 3, arrows). By day 38, with the
complete resolution of inflammation, the bone architecture of arthritic mice was similar to
that of nonarthritic control mice.
Thus, using quantitative molecular and morphologic parameters, we characterized 3
reproducible phases in this model of inflammation resolution, including: 1) an inflammatory
phase (days 0–10) exemplified by expression of proinflammatory cytokines and RANKL
that induce bone erosion, 2) a resolution phase (days 10–28) of abating proinflammatory
cytokine and catabolic factor expression leading to declining osteoclastogenesis, and 3) a
remodeling and repair phase (day 28 onward).
Effect of resolution of inflammation on osteoblast-mediated bone formation and erosion
repair
Given the apparently normal bone architecture observed on days 38 and 58 by micro-CT, we
hypothesized that the reduction of inflammation promoted osteoblast-mediated bone
formation. To quantify the extent of osteoblast activity, in vivo fluorochrome incorporation
at inflammation–bone interfaces was assessed using dynamic histomorphometry. Little
incorporation of alizarin was evident at inflammation–bone interfaces in the navicular bone
on day 10, when peak inflammation was observed (Figure 4A). Quantification on day 10
revealed a slight decrease in MS/BS in arthritic mice compared with nonarthritic controls
(Figure 4B). In contrast, with resolution of inflammation, significant alizarin and calcein
incorporation was observed at inflammation–bone interfaces on days 28, 38, and 48 (Figure
4A). At these time points, a statistically significant increase in MS/BS in arthritic mice
compared with nonarthritic controls indicated an increase in the mineralizing activity of
osteoblasts at erosion sites (Figure 4B). In addition, there was a statistically significant
increase in the MAR, a measure of the activity of individual osteoblasts (Figure 4C), and
BFR/BS, a value calculated from the MAR and MS/BS (Figure 4D). The MAR and BFR
could not be calculated on day 10, because only a single label (alizarin) can be administered
within this time period.
To observe bone formation over time, 2 fluorochromes were administered at alternating
intervals every 10 days throughout the course of arthritis, resulting in a total of 6
fluorochrome injections over the course of 58 days (3 alizarin, 3 calcein). Strikingly,
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multiple layers of fluorochrome incorporation were observed over the 58-day period
following the induction of arthritis, indicating that bone formation was a dynamic process
that occurred throughout the resolution and remodeling phases (results not shown).
The presence of mature osteoblasts at inflammation–bone interfaces paralleled the increase
in bone formation that occurred with resolution of inflammation. At the time of peak
inflammation (day 10), there was limited to no expression of alkaline phosphatase, a mid-
stage osteoblast marker, or OCN, a late-stage osteoblast marker, by cells along the
inflammation–bone interfaces (Figures 5A and B). However, as inflammation abated during
the resolution phase, there was a progressive increase in the number of osteoblasts
expressing alkaline phosphatase and OCN, as well as an increase in the number of these
cells lining the eroded endosteal bone surfaces. Alkaline phosphatase–expressing cells were
observed beginning on day 15, followed by an abundance of osteoblasts expressing OCN on
endosteal bone surfaces as well as some eroded cortical surfaces by day 21. From day 28
onward, there were fewer alkaline phosphatase– and OCN-expressing osteoblasts and
surfaces lined by these cells. Taken together, these results demonstrate that osteoblasts
populate bone surfaces and synthesize bone in parallel with declining inflammation.
Alterations in expression of Wnt signalling factors with resolution of inflammation
To address mechanisms related to osteoblast maturation and bone formation at eroded bone
surfaces, we investigated the impact of inflammation on the expression of antagonists and
agonists of the Wnt signaling pathway. Within the synovial tissue of arthritic mice,
induction of sFRP1 and sFRP2 mRNA expression was observed in relation to nonarthritic
controls on day 10 (Figures 6A and B). The timing of this expression corresponded to the
inflammatory phase of the model, when inflammation peaks and bone formation is
suppressed. The expression of sFRP1 and sFRP2 mRNA subsequently declined as
inflammation resolved, until day 28, when the expression levels in arthritic mice were
similar to those in nonarthritic controls. In contrast, DKK1 mRNA was detected later in the
inflammatory process, with peak ∼2-fold expression occurring on days 28 and 38 (Figure
6C).
We further investigated the ability of declining inflammation to promote the expression of
anabolic Wnt ligands. As inflammation declined, the mRNA expression of Wnt10b, a Wnt
agonist that promotes osteoblastogenesis and in vivo bone formation (30), was up-regulated
in arthritic mice compared with that in nonarthritic controls (Figure 6D). Although mRNA
levels were low, we also examined the trends of DKK2 and Wnt7b expression in this model.
Synovial mRNA expression of DKK2, a Wnt antagonist that promotes matrix
mineralization, was suppressed at the peak of inflammation and bone erosion (day 10). In
contrast, expression increased during the resolution phase of inflammation (Figure 6E). Up-
regulation of DKK2 mRNA correlated with a reciprocal down-regulation of the canonical
Wnt signaling agonist, Wnt7b (Figure 6F). A similar reciprocal relationship between DKK2
and Wnt7b expression in osteoblasts has been reported previously (31). These results
demonstrate that although inflammation induces expression of Wnt antagonists that inhibit
osteoblast differentiation, the reduction in inflammation up-regulates anabolic and pro–
matrix mineralization Wnt signaling factors (Figure 6G).
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Discussion
Pathologic bone loss in inflammatory diseases is characterized by an imbalance of
osteoclast-mediated bone resorption relative to osteoblast-mediated bone formation,
resulting in a net loss of bone. We previously showed in a murine model of inflammatory
arthritis that the presence of inflammation at sites of articular bone erosion correlated with
limited osteoblast activity (15). This observation demonstrated that inflammation impairs the
ability of osteoblasts to form bone and raised the question as to whether resolution of
inflammation would promote osteoblast-mediated bone formation. We adapted the serum
transfer model of arthritis, based on the original observations by Korganow et al (20), in
order to establish the phases of inflammation-induced bone erosion repair and demonstrated
that in the setting of declining inflammation, bone formation occurs, leading to repair of
focal articular bone loss.
By elucidating the temporal sequence of bone formation relative to the inflammatory
process in this model, an understanding of the key events leading to inflammation-induced
bone loss and repair was established. The inflammatory phase was characterized by
decreased mineralized bone surface and by a paucity of alkaline phosphatase− and OCN-
expressing osteoblasts at eroded surfaces, consistent with our previous studies (15). During
the resolution phase in the present study, osteoblasts prominently expressing OCN populated
previous inflammation–bone interfaces, in particular endosteal surfaces, coincident with a
significant increase in MS/BS, MAR, and BFR. This increase in MS/BS, MAR, and BFR
persisted through the repair and remodeling phase, demonstrating that resolving
inflammation stimulates repair of bone loss.
Repair of inflammation-induced bone erosion in this model is a result of both an increase in
osteoblast activity and a reciprocal decrease in osteoclast-mediated bone resorption. The
removal of arthritogenic stimuli results in a decrease in expression of proinflammatory
cytokines and RANKL, leading to a decrease in osteoclast formation and bone resorption.
Activation of the canonical Wnt/β-catenin pathway has been shown to up-regulate OPG
expression to inhibit osteoclast differentiation (32,33). Our data demonstrate an increase in
synovial OPG expression concurrent with the decline in osteoclast formation with resolving
inflammation, consistent with activation of this pathway.
Previously, synovial fibroblasts in RA have been shown to express inhibitors of the Wnt
signaling pathway, including DKK1, sFRP1, sFRP3, and sFRP4 (9,34,35). There is also
increasing evidence implicating the Wnt antagonists, DKK1 (9) and sFRP1 (15,36), as
factors that suppress osteoblast activity in models of inflammatory bone loss. This study
establishes that expression of both sFRP1 and sFRP2 is induced with inflammation and
declines with decreasing inflammation.
Restoration of osteoblast activity following the decline of inflammation in this study clearly
demonstrates that inflammation perturbs the balance of anabolic bone signaling, with
profound effects on the Wnt signaling pathway. Elevated DKK1 expression has been
associated with inflammatory bone loss and suppression of osteoblast activity in RA (9) as
well as in multiple myeloma (37), while prophylactic DKK1 blockade stimulated periosteal
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osteophyte formation in the human TNFα–transgenic (hTNF-Tg) murine model of RA (9).
DKK1 is expressed in the synovium of arthritic hTNF-Tg mice and is up-regulated in
cultured human RA and murine synovial fibroblasts. In the current study, we observed that
synovial DKK1 mRNA expression was not significantly elevated at the time point examined
during the inflammatory phase of serum transfer–induced arthritis (day 10) but trended
upward later in the course of arthritis (days 28 and 38), during the phase of resolving
inflammation. However, as previously demonstrated, when more robust inflammation was
induced in this model following 4 injections of arthritogenic serum, an up-regulation of
DKK1 mRNA was seen during the period of peak inflammation (15). In the model of serum
transfer–induced arthritis, IL-1β is a predominant proinflammatory cytokine (28), and as
such, a pattern of Wnt antagonist expression different from that seen in the hTNF-Tg model
may ensue. In addition, in the serum transfer model of arthritis, expression of DKK1 mRNA
is low; therefore, it is difficult to draw conclusions about the impact of DKK1 on osteoblast
function following the resolution of inflammation in this study.
Regulated Wnt agonist expression directs vertebrate limb and synovial joint development
(38,39) and as such may promote bone formation. In this study, bone formation correlated
with increasing synovial expression of Wnt10b, a canonical Wnt agonist. Overexpression of
Wnt10b was shown to increase bone mass and the trabecular number by increasing
osteoblast number and osteoblast activity, while deletion of Wnt10b led to a decrease in
bone formation (30). In this study, the up-regulation of Wnt10b in the synovium following
resolution of inflammation is a likely mechanism contributing to bone formation.
The expression of Wnt7b is down-regulated with declining inflammation. Previous studies
have demonstrated that Wnt7b mRNA is expressed by trabecular osteoblasts in vivo (40),
and that expression peaks early during osteoblast differentiation in vitro (31,40), suggesting
that Wnt7b may promote bone formation. Importantly, down-regulation of Wnt7b
expression in osteoblasts correlates with induction of expression of DKK2, a Wnt antagonist
that promotes osteoblast maturation and mineralization of newly synthesized bone matrix
(31). Indeed, in this study, we observed a similar inverse relationship between Wnt7b and
DKK2 expression in synovial tissue, which was regulated by the presence of inflammation.
With resolution of inflammation, decreasing Wnt7b expression correlates with the
expression of DKK2 by osteoblasts recruited to the sites of bone erosion, which could
subsequently promote osteoblast maturation and direct mineralization of the newly formed
bone at erosion sites.
These findings provide insight into an important conundrum in clinical disease, the relative
lack of repair of articular erosions in RA patients in whom clinical parameters suggest
excellent disease control or even remission. Therapy with potent antiinflammatory drugs
such as anti-TNF agents has been shown to slow or halt the progression of articular erosion,
but repair of erosions is still limited, even when sensitive radiographic techniques such as
high-resolution computed tomography are employed to identify repair (41). Our findings in
this murine model of RA demonstrate that if inflammation is controlled, bone formation and
repair of erosions occur and suggest that in clinical disease in which repair is not seen,
inflammation in synovial tissues likely persists. Recent clinical data are consistent with this
notion. When studying patients with RA who were receiving disease-modifying
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antirheumatic drug therapy and in whom disease was deemed to be in clinical remission,
Brown et al demonstrated that subclinical inflammation could be identified by the sensitive
techniques of magnetic resonance imaging (MRI) and musculoskeletal ultrasonography.
Furthermore, a direct association between ongoing synovitis and structural progression was
shown (42,43). In addition, in studies of patients with disease judged to be in clinical
remission, MRI, as well as synovial biopsies combined with ultrasonography or MRI,
demonstrated the persistence of synovitis (44,45). Our findings, however, cannot exclude the
possibility that other environmental, cellular, and/or epigenetic changes could have occurred
that alter Wnt antagonist and agonist expression independent of the requirement of ongoing
inflammation.
In conclusion, these studies in a murine model of resolving inflammation provide a direct
demonstration that reduced inflammation within the bone microenvironment favors the
restoration of osteoblast function and the repair of focal bone erosions. Furthermore, by
altering the expression of Wnt antagonists and agonists in the synovium, inflammation
significantly contributes to the regulation of Wnt signaling, a pathway that ultimately
determines the fate of bone. Therefore, aggressive control of synovial inflammation and
close monitoring of synovitis with sensitive radiologic techniques may be required in order
to stimulate bone formation and restore bone structural integrity in diseases involving
inflammation-induced bone loss.
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Figure 1.
Discontinuation of arthritogenic serum injections promotes resolution of proinflammatory
cytokine expression and osteoclastogenesis. A, Clinical inflammation scores of arthritic and
nonarthritic mice. Values are the mean ± SD of 3 independent experiments (n = 7–8 mice
per time point). B–F, Expression of interleukin-1β (IL-1β) (B), tumor necrosis factor (TNF)
(C), matrix metalloproteinase 13 (MMP-13) (D), RANKL (E), and osteoprotegerin (OPG)
(F) in synovial tissue as determined by quantitative reverse transcription–polymerase chain
reaction (n = 7–8 mice per time point). * = P < 0.05; ** = P < 0.01; *** = P < 0.001 versus
day 10. G, Serum tartrate-resistant acid phosphatase 5b (TRAP-5b) levels in arthritic and
nonarthritic mice combined from 2 independent experiments (n = 7–8). ** = P < 0.01 versus
nonarthritic controls on day 10. Each symbol represents the mean of duplicate samples for a
single mouse. Horizontal lines represent the group means.
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Figure 2.
Histologic evaluation demonstrates resolution of inflammation and osteoclast-mediated bone
resorption. A and B, Representative serial hematoxylin and eosin–stained sections (A) and
tartrate-resistant acid phosphatase–stained sections (B) of the navicular bone of nonarthritic
mice (left panel) and arthritic mice (right panels) (n = 3 independent experiments). Arrows
denote pannus tissue and inflammation in A and osteoclasts in B. The arrowhead indicates
a full-thickness cortical defect. Bars = 200 μm. C and D, Histologic quantification of
inflammation (C) and midfoot erosion (D) in arthritic mice and nonarthritic mice. Each
symbol represents the mean histologic score per mouse (n = 7–8 mice per time point).
Horizontal lines represent the group means.
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Figure 3.
Restoration of cortical and trabecular bone architecture correlates with resolution of
inflammation. Sagittal images of the ankle and midfoot bones are shown. Arrows indicate
full cortical breaks in the midfoot bones due to osteoclast-mediated erosion. At each time
point, 3–4 arthritic mice and 4 nonarthritic mice were examined. Original magnification × 3.
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Figure 4.
Quantification of bone histomorphometric parameters demonstrates increased bone
formation with inflammation resolution. A, Representative images of alizarin (red) and
calcein (green) incorporation in 2 independent experiments are shown. Mice killed on day
10 received a single injection of alizarin on day 5. For quantitative analysis, mice were given
alizarin 13 days prior to being killed and calcein 3 days prior to being killed. Bars = 100 μm.
B–D, Fluorochrome incorporation at navicular erosion sites was used to quantify the bone
formation parameters mineralized surface/total bone surface (MS/BS) (B), mineral
apposition rate (MAR) (C), and bone formation rate/total bone surface (BFR/BS) (D). Each
symbol represents a single nonarthritic mouse (n = 15) or a single arthritic mouse (n = 4 on
day 10, n = 7–8 on days 28, 38, and 48). Horizontal lines represent the means. * = P < 0.05;
** = P < 0.01; *** = P < 0.001 versus nonarthritic controls.
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Figure 5.
Mature osteoblasts are identified at eroded surfaces during the resolution phase of
inflammation. Histologic sections show in situ hybridization for alkaline phosphatase (AlkP)
(A) and osteocalcin (OCN) (B) mRNA expression at eroded bone surfaces in the navicular
bone of arthritic mice (n = 3–4 mice per time point in 2 independent experiments). Positive
cells are identified by purple staining. Arrows denote areas of mRNA expression.
Hybridization with sense probes was used as the negative control. Bars = 100 μm.
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Figure 6.
Resolution of inflammation and erosion repair parallel alterations in Wnt antagonist and
agonist mRNA expression. A–F, Synovial expression of secreted frizzled-related protein 1
(sFRP1) (A), sFRP2 (B), DKK1 (C), Wnt10b (D), DKK2 (E), and Wnt7b (F) mRNA. Gene
expression was calculated relative to the average gene expression in nonarthritic controls (n
= 7–8 mice per time point). Each symbol represents the mean of duplicate samples for a
single mouse. Horizontal lines represent the group means. * = P < 0.05; ** = P < 0.01; ***
= P < 0.001 versus day 10. G, Expression patterns of Wnt antagonists and agonists over the
course of inflammation, resolution, and remodeling.
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